Imad El Majzoub1, Aiham Qdaisat1, Kyaw Z Thein2, Myint A Win1, Myat M Han1, Kalen Jacobson1, Patrick S Chaftari1, Michael Prejean3, Cielito Reyes-Gibby1, Sai-Ching J Yeung4. 1. Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Division of Hematology/Oncology, Texas Tech University Health Sciences Center, Lubbock, TX. 3. Division of Nursing, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: syeung@mdanderson.org.
Abstract
STUDY OBJECTIVE: Cancer immunotherapy is evolving rapidly and is transforming cancer care. During the last decade, immune checkpoint therapies have been developed to enhance the immune response; however, specific adverse effects related to autoimmunity are increasingly apparent. This study aims to fill the knowledge gap related to the spectrum of immune-related adverse effects among cancer patients visiting emergency departments (EDs). METHODS: We performed a retrospective review of patients treated with immune checkpoint therapy who visited the ED of a comprehensive cancer center between March 1, 2011, and February 29, 2016. Immune-related adverse effects from the ED visits were identified and profiled. We analyzed the association of each immune-related adverse effect with overall survival from the ED visit to death. RESULTS: We identified 1,026 visits for 628 unique patients; of these, 257 visits (25.0%) were related to one or more immune-related adverse effects. Diarrhea was the most common one leading to an ED visit. The proportions of ED visits associated with diarrhea, hypophysitis, thyroiditis, pancreatitis, or hepatitis varied significantly by immune checkpoint therapy agent. Colitis was significantly associated with better prognosis, whereas pneumonitis was significantly associated with worse survival. CONCLUSION: Cancer patients treated with ipilimumab, nivolumab, or pembrolizumab may have a spectrum of immune-related adverse effects that require emergency care. Future studies will need to update this profile as further novel immunotherapeutic agents are added.
STUDY OBJECTIVE:Cancer immunotherapy is evolving rapidly and is transforming cancer care. During the last decade, immune checkpoint therapies have been developed to enhance the immune response; however, specific adverse effects related to autoimmunity are increasingly apparent. This study aims to fill the knowledge gap related to the spectrum of immune-related adverse effects among cancerpatients visiting emergency departments (EDs). METHODS: We performed a retrospective review of patients treated with immune checkpoint therapy who visited the ED of a comprehensive cancer center between March 1, 2011, and February 29, 2016. Immune-related adverse effects from the ED visits were identified and profiled. We analyzed the association of each immune-related adverse effect with overall survival from the ED visit to death. RESULTS: We identified 1,026 visits for 628 unique patients; of these, 257 visits (25.0%) were related to one or more immune-related adverse effects. Diarrhea was the most common one leading to an ED visit. The proportions of ED visits associated with diarrhea, hypophysitis, thyroiditis, pancreatitis, or hepatitis varied significantly by immune checkpoint therapy agent. Colitis was significantly associated with better prognosis, whereas pneumonitis was significantly associated with worse survival. CONCLUSION:Cancerpatients treated with ipilimumab, nivolumab, or pembrolizumab may have a spectrum of immune-related adverse effects that require emergency care. Future studies will need to update this profile as further novel immunotherapeutic agents are added.
Authors: Frank Rojas; Sharia Hernandez; Rossana Lazcano; Caddie Laberiano-Fernandez; Edwin Roger Parra Journal: Front Oncol Date: 2022-06-27 Impact factor: 5.738
Authors: Kai-Li Liang; Sean Tackett; Samantha Myers; Julie R Brahmer; Ilene S Browner; David S Ettinger; Patrick M Forde; Russell K Hales; Christine L Hann; Vincent K Lam; Kristen A Marrone; Tricia Patel; Valerie Peterson; Sarah Sagorsky; Michelle Turner; Khinh R Voong; Jarushka Naidoo; Josephine L Feliciano Journal: Curr Oncol Date: 2022-06-17 Impact factor: 3.109
Authors: Jacopo Davide Giamello; Giuseppe Lauria; Andrea Antonuzzo; Paolo Bossi; Bartolomeo Lorenzati; Gianmauro Numico Journal: Support Care Cancer Date: 2022-01-26 Impact factor: 3.359
Authors: Jeffrey M Caterino; David Adler; Danielle D Durham; Sai-Ching Jim Yeung; Matthew F Hudson; Aveh Bastani; Steven L Bernstein; Christopher W Baugh; Christopher J Coyne; Corita R Grudzen; Daniel J Henning; Adam Klotz; Troy E Madsen; Daniel J Pallin; Cielito C Reyes-Gibby; Juan Felipe Rico; Richard J Ryan; Nathan I Shapiro; Robert Swor; Arvind Venkat; Jason Wilson; Charles R Thomas; Jason J Bischof; Gary H Lyman Journal: JAMA Netw Open Date: 2019-03-01